Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
Thursday, January 08, 2026DISCO Pharmaceuticals DISCO today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCOs proprietary platform
Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
Thursday, January 08, 2026Arbele a biotechnology company focused on developing innovative targeted cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation ODD to ARB
Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps
Wednesday, January 07, 2026GSK plc today announced the approval of Exdensur depemokimab by Japans Ministry of Health Labour and Welfare MHLW as a treatment for bronchial asthma limited to severe or refractory patients whose asthma symptoms
Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes
Wednesday, January 07, 2026Thermo Fisher Scientific Inc the world leader in serving science today announced the enrollment of the first patient in the new PPD CorEvitas Obesity Registry This prospective observational registry will generate realworld evidence
Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Tuesday, January 06, 2026The US Food and Drug Administration FDA has accepted for priority review the supplemental biologic license application sBLA for Tzield teplizumabmzwv to expand the current age indication from eight years and above
Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)
Tuesday, January 06, 2026GSK plc today announced that Chinas National Medical Products Administration NMPA has approved Nucala mepolizumab as addon maintenance treatment of adult patients with inadequately controlled COPD characterised by raised blood eosinophils
